DOM

DOM arrives like a geological event. For the first two hours -- sometimes three -- there is almost nothing to report. A mild buzz in the body, a slight tightening in the stomach, perhaps a barely perceptible sharpening of the visual field. If you are accustomed to LSD's thirty-minute onset or mushrooms' forty-five-minute wave, this silent opening stretch feels like an eternity. The temptation to redose is powerful and must be resisted absolutely -- the 1967 STP disaster was caused by exactly this impatience. DOM is coming. It does not care about your timeline.

Around the third hour, the experience begins to gather mass. A deep, resonant stimulation builds in the body -- not the jittery, peripheral push of caffeine or the sharp edge of amphetamine, but something tectonic, as though a great weight is slowly lifting from beneath the surface of awareness. Heart rate increases noticeably. Jaw tension settles in. The pupils dilate wide. Colors begin not just to brighten but to reveal dimensions of themselves that you have never seen. The green of a leaf is no longer a color -- it is a spectrum, an event, a thing with depth and structure and meaning. There is a growing sense that something enormous is about to happen, and you are right.

The peak arrives between hours four and six, and it arrives with a profundity that can stagger even experienced psychonauts. The visual world transforms utterly. Geometric patterns of extraordinary complexity emerge from every surface, but they have a solidity and depth that sets DOM apart from lighter psychedelics. Patterns do not hover on surfaces; they exist within them, as though the molecular structure of matter itself has become visible. The experience has been described as seeing the source code of reality, and while that sounds grandiose, it captures something essential. Colors become so saturated they feel almost audible -- a phenomenon of synesthesia that is more commonly reported with DOM than with most other psychedelics. The visual field has a distinctly "electric" quality, crisp and luminous and somehow more structured than the fluid, organic visuals of tryptamines.

Cognitively, DOM at its peak is a place of extraordinary depth. Thoughts do not merely accelerate -- they deepen. Questions about identity, existence, time, and meaning arise with an urgency and emotional weight that can be either transformative or terrifying, sometimes both within the same hour. The emotional landscape is vast: ecstatic wonder, existential dread, oceanic peace, and raw vulnerability cycle through in waves. There is a quality of significance to everything -- every object, every thought, every sensation feels loaded with meaning and importance. Music becomes transcendent, acquiring spatial dimensions and emotional power that make it feel like the most important thing in the world.

The body maintains its driven stimulation throughout. Heart rate stays elevated. Jaw clenching requires attention. Temperature regulation may fluctuate -- waves of warmth alternating with chills. Movement feels purposeful but slightly mechanical, as though the body is operating on a different frequency than usual. Appetite is suppressed completely.

And then you realize something: you are only at hour six. The peak alone lasts another four to six hours. The total experience stretches fourteen to twenty hours. This is the great challenge and the great reward of DOM -- it demands that you surrender your day, your night, and possibly part of the following morning to a single, sustained, profound psychedelic state. The descent is a marathon of slowly diminishing intensity, during which colors remain vivid and the cognitive depth gradually releases its grip. Sleep is impossible until the very end. When it finally comes, it is heavy and dreamless. The following day carries a bone-deep tiredness and, often, a quiet sense of awe -- the feeling of having been somewhere genuinely profound and emerging changed by it.

Receptor Profile

DOM acts as a potent agonist at serotonin 5-HT2A and 5-HT2C receptors, the primary mediators of its psychedelic effects. Unlike weaker partial agonists such as 2C-D or mescaline, DOM approaches full agonist efficacy in most functional assays -- binding with high affinity and producing robust intracellular signaling at single-digit milligram doses. This combination of high affinity and high efficacy is what makes DOM so potent: it does not merely nudge the serotonin system, it drives it with force.

DOM also shows significant binding at 5-HT2B receptors, raising theoretical concerns about cardiac valvulopathy with chronic use (the same mechanism responsible for fenfluramine-related heart valve damage). For a substance used once or rarely, this is likely clinically irrelevant. Additionally, DOM has modest affinity for adrenergic alpha-1 and alpha-2 receptors, contributing to its cardiovascular effects: elevated blood pressure, peripheral vasoconstriction, and the "driven" physical quality that distinguishes it from tryptamine psychedelics.

The Amphetamine Backbone

DOM is a substituted amphetamine, carrying the alpha-methyl group on the ethylamine side chain that distinguishes amphetamines from phenethylamines. This single structural modification has three important consequences:

1. MAO resistance -- The alpha-methyl group makes DOM a poor substrate for monoamine oxidase, the enzyme that rapidly degrades phenethylamines like mescaline and the 2C series. This is the primary reason DOM lasts 14-20 hours while structurally similar 2C-D lasts 4-6 hours
2. Enhanced blood-brain barrier penetration -- The increased lipophilicity from the methyl group improves CNS bioavailability, contributing to DOM's potency at low milligram doses
3. Minimal monoamine transporter activity -- Unlike classical amphetamines (dextroamphetamine, methamphetamine), DOM shows negligible activity at dopamine and norepinephrine transporters. Its stimulant effects arise from serotonergic activation and downstream catecholamine release, not from direct monoamine reuptake inhibition or release. This is why DOM feels "stimulating" without feeling like speed

Why It Lasts So Long

DOM's 14-20 hour duration -- roughly three to four times longer than LSD and five times longer than psilocybin -- results from a convergence of pharmacokinetic and pharmacodynamic factors:

• MAO resistance: The alpha-methyl group prevents the rapid enzymatic degradation that limits most phenethylamine psychedelics to 4-8 hours
• Slow hepatic metabolism: Clearance proceeds primarily via CYP2D6-mediated O-demethylation of the methoxy groups at positions 2 and 5, a pathway that operates slowly for this particular substrate
• Active metabolites: Several DOM metabolites retain psychoactive properties at 5-HT2A receptors, extending subjective effects beyond the parent compound's elimination half-life
• Slow receptor dissociation: DOM binds tightly to 5-HT2A receptors and releases slowly, maintaining receptor activation even as plasma levels decline

The net result is that a single dose produces effects that outlast a full night's sleep. This is not a substance you can take in the evening and sleep off by morning.

Pharmacokinetics

Oral absorption is complete, with onset at 1-3 hours -- significantly slower than LSD (30-90 minutes). Peak effects occur at 4-6 hours, with the peak plateau sustaining for an additional 4-8 hours. Total duration is 14-20 hours, with some users reporting residual stimulation at 24 hours. The slow onset is clinically important: it is the direct cause of the 1967 STP disaster, where users redosed before the first dose had taken effect.

Tolerance

Tolerance builds rapidly after a single dose. A second dose taken within 48 hours produces substantially reduced effects. Cross-tolerance with all serotonergic psychedelics (LSD, psilocybin, mescaline, 2C compounds) is complete. Full tolerance reset requires approximately 7-14 days, though some users report needing longer. This rapid tolerance is self-limiting and effectively prevents daily use.

DOM was first synthesized by Alexander Shulgin in 1963-1964 while working as a research chemist at Dow Chemical Company in Midland, Michigan. The compound emerged from Shulgin's systematic exploration of 2,5-dimethoxyamphetamine derivatives, in which he varied the substituent at the 4-position to understand how different groups affected psychedelic potency, character, and duration. By placing a methyl group -- the smallest possible alkyl substituent -- at the 4-position, Shulgin created a compound of remarkable potency: full psychedelic effects at just 3-5 mg, with a duration exceeding 14 hours. He recognized immediately that DOM demonstrated a fundamental principle of psychedelic pharmacology -- that simple substitutions on the amphetamine backbone could produce extraordinary changes in potency and duration.

Shulgin published his findings, and DOM entered the small network of researchers studying psychedelic structure-activity relationships. For several years, it remained a laboratory curiosity. That changed abruptly in 1967.

In mid-June 1967, underground chemist Augustus Owsley Stanley III -- already legendary as the primary supplier of LSD to the San Francisco counterculture -- produced a large batch of DOM tablets. On June 21st, during the Summer Solstice celebration in Golden Gate Park, thousands of these tablets were distributed freely. They were branded "STP," ostensibly standing for "Serenity, Tranquility, and Peace" (also a play on the popular motor oil additive). Each tablet contained approximately 20 mg of DOM -- roughly four times what would now be considered a strong dose.

The underground press, including The Berkeley Barb and the San Francisco Oracle, had enthusiastically promoted STP as a new, legal alternative to LSD, which California had criminalized in October 1966. But DOM's pharmacology was fundamentally different from LSD's. Its onset was slow -- one to three hours, compared to LSD's thirty to ninety minutes. Users accustomed to LSD's faster timeline felt nothing after an hour and took second or third tablets. By the time the first dose reached full effect, they were deep into a massive, uncontrolled overdose that would last the better part of a day.

The consequences were immediate and severe. The Haight-Ashbury Free Medical Clinic, founded just days earlier by Dr. David E. Smith, treated its first STP case that evening -- a nineteen-year-old man who had been awake for two days. That same night, over twenty-three additional patients arrived at the clinic. In total, thirty-two patients were treated at the free clinic and another thirteen at San Francisco General Hospital over the following days. Dr. Smith later estimated that for every patient who sought treatment, another thirty-nine were enduring bad trips unsupervised in the community -- suggesting over a thousand adverse experiences from a single distribution event.

The crisis deepened when emergency physicians attempted to treat distressed patients with chlorpromazine (Thorazine), the standard antipsychotic used for LSD crises. While effective for LSD, chlorpromazine intensified DOM's effects, worsening agitation and delirium rather than resolving it. This pharmacological interaction -- unexpected and poorly understood at the time -- made an already chaotic situation genuinely dangerous and was subsequently recognized as a critical lesson in emergency psychedelic medicine.

The STP disaster had lasting consequences. It directly influenced the inclusion of DOM in Schedule I of the Controlled Substances Act when that legislation was enacted in 1970. It contributed to the broader cultural backlash against psychedelics that ended the first wave of psychedelic research. And it established a principle that the harm reduction community still emphasizes: that unfamiliar psychoactive substances require conservative dosing, patience during onset, and specific knowledge of emergency management protocols rather than generic "trip killer" approaches.

Shulgin continued to regard DOM as one of his most significant compounds. It appears as entry #68 in PiHKAL (1991) with a +++ rating -- his second-highest mark -- and he wrote about it with evident respect for both its power and its importance in understanding psychedelic pharmacology. The DOx series it launched (DOB, DOI, DOC, DON) became one of the most important families in the study of structure-activity relationships for hallucinogenic amphetamines.